CVE:RX BioSyent (RX) Stock Price, News & Analysis C$10.08 +0.17 (+1.72%) (As of 07/26/2024 05:27 PM ET) Add Compare Share Share Today's RangeC$9.92▼C$10.0850-Day RangeC$9.00▼C$10.5052-Week RangeC$7.46▼C$10.75Volume714 shsAverage Volume6,594 shsMarket CapitalizationC$116.83 millionP/E Ratio17.38Dividend Yield1.79%Price TargetN/A Stock AnalysisStock AnalysisChartEarningsHeadlinesInsider TradesStock AnalysisChartEarningsHeadlinesInsider Trades Get BioSyent alerts: Email Address Ad Porter & CompanyObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happen, that the 22nd Amendment makes it impossible. But as I explained on live radio years ago, “he could have a proxy… while he remains in control of the administration much like Putin did in Russia.” Please, watch this now before it’s too late. About BioSyent Stock (CVE:RX)BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; Combogesic to manage mild to moderate acute pain and reduction of fever in adults; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. BioSyent Inc. was founded in 2006 and is headquartered in Mississauga, Canada.Read More RX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RX Stock News HeadlinesMay 26, 2024 | finance.yahoo.comBioSyent (CVE:RX) Could Be A Buy For Its Upcoming DividendMay 21, 2024 | finance.yahoo.comBioSyent (CVE:RX) Has Affirmed Its Dividend Of CA$0.045July 27, 2024 | Paradigm Press (Ad)Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.May 10, 2024 | finance.yahoo.comIncreases to CEO Compensation Might Be Put On Hold For Now at BioSyent Inc. (CVE:RX)May 9, 2024 | msn.comAMD RDNA 4: Everything we know about the RX 8000 seriesApril 16, 2024 | finanznachrichten.deBioSyent Inc.: BioSyent Announces Extension of RepaGyn and Proktis-M AgreementApril 4, 2024 | finance.yahoo.comBioSyent Inc.'s (CVE:RX) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?April 3, 2024 | markets.businessinsider.comFeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Ninth Consecutive YearJuly 27, 2024 | Paradigm Press (Ad)Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.March 21, 2024 | finanznachrichten.deBioSyent Inc.: BioSyent Releases Financial Results for Fourth Quarter and Full Year 2023March 16, 2024 | uk.investing.comEarnings call: BioSyent Inc. reports robust growth in Q4 and FY 2023February 21, 2024 | markets.businessinsider.comBioSyent Named to 2024 TSX Venture 50February 17, 2024 | seekingalpha.comRX:CA BioSyent Inc.February 6, 2024 | markets.businessinsider.comBioSyent Declares First Quarter 2024 DividendNovember 24, 2023 | finance.yahoo.comIs It Smart To Buy BioSyent Inc. (CVE:RX) Before It Goes Ex-Dividend?November 20, 2023 | finance.yahoo.comBioSyent Announces the Availability of Gelclair® in CanadaNovember 20, 2023 | markets.businessinsider.comBloom Burton Believes Biosyent (RX) Won’t Stop HereNovember 16, 2023 | finance.yahoo.comBioSyent Releases Q3 and YTD 2023 Financial ResultsSee More Headlines Receive RX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioSyent and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/16/2024Today7/26/2024Next Earnings (Estimated)8/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolCVE:RX CUSIPN/A CIKN/A Webwww.biosyent.com Phone+1-905-2060013FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)C$0.58 Trailing P/E Ratio17.38 Forward P/E Ratio18.18 P/E GrowthN/ANet IncomeC$6.46 million Net Margins20.45% Pretax MarginN/A Return on Equity18.97% Return on Assets11.39% Debt Debt-to-Equity Ratio3.51 Current Ratio6.48 Quick Ratio6.91 Sales & Book Value Annual SalesC$31.59 million Price / Sales3.70 Cash FlowC$3.28 per share Price / Cash Flow3.07 Book ValueC$2.96 per share Price / Book3.41Miscellaneous Outstanding Shares11,590,000Free FloatN/AMarket CapC$116.83 million OptionableNot Optionable Beta0.93 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. René C. Goehrum (Age 65)Chairman, CEO & President Comp: $594.99kMr. Robert J. MarchVP of Finance & CFOMr. Joost van der MarkVice President of Corporate DevelopmentMs. Neelu AtwalDirector of Human ResourcesKey CompetitorsAurora CannabisTSE:ACBSupreme CannabisTSE:FIREOrganigramTSE:OGIESSA PharmaCVE:EPICardiol TherapeuticsTSE:CRDLView All CompetitorsInsidersSharan RaghubirSold 423 sharesTotal: C$4,246.92 ($10.04/share)Sharan RaghubirSold 1,755 sharesTotal: C$17,566.50 ($10.01/share)Rene GoehrumSold 1,522 sharesTotal: C$14,276.36 ($9.38/share)Peter Douglas LockhardSold 432 sharesTotal: C$3,866.40 ($8.95/share)BioSyent Inc.Bought 5,100 shares on 4/29/2024Total: C$43,627.95 ($8.55/share)View All Insider Transactions RX Stock Analysis - Frequently Asked Questions How have RX shares performed this year? BioSyent's stock was trading at C$9.22 on January 1st, 2024. Since then, RX shares have increased by 9.3% and is now trading at C$10.08. View the best growth stocks for 2024 here. How were BioSyent's earnings last quarter? BioSyent Inc. (CVE:RX) announced its quarterly earnings data on Thursday, May, 16th. The company reported $0.15 earnings per share for the quarter, beating analysts' consensus estimates of $0.08 by $0.07. The firm earned $7.73 million during the quarter, compared to analysts' expectations of $7.90 million. BioSyent had a net margin of 20.45% and a trailing twelve-month return on equity of 18.97%. How do I buy shares of BioSyent? Shares of RX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What other stocks do shareholders of BioSyent own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioSyent investors own include Aurora Cannabis (ACB), Canadian National Railway (CNR), Bank of Nova Scotia (BNS), Cross Timbers Royalty Trust (CRT), Dollarama (DOL) and Enbridge (ENB). This page (CVE:RX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioSyent Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioSyent With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.